Patterns of Substance Use Before and After Hospitalization among Patients Seen by an Inpatient Addiction Consult Service: A Latent Transition Analysis

Caroline King  
*Oregon Health & Science University*

Christina Nicolaidis  
*OHSU-PSU School of Public Health*, christina.nicolaidis@pdx.edu

P. Todd Korthuis  
*OHSU-PSU School of Public Health*

Kelsey C. Priest  
*OHSU-PSU School of Public Health*

Honora Englander  
*Oregon Health & Science University*

Follow this and additional works at: [https://pdxscholar.library.pdx.edu/socwork_fac](https://pdxscholar.library.pdx.edu/socwork_fac)

---

**Citation Details**

Title: **Patterns of substance use before and after hospitalization among patients seen by an inpatient addiction consult service: a latent transition analysis**

Authors: Caroline King, MPH\(^{1,2}\)  
Christina Nicolaidis, MD, MPH\(^{3,4,5}\)  
P. Todd Korthuis, MD, MPH\(^{4,5}\)  
Kelsey C. Priest, PhD, MPH\(^{2}\)  
Honora Englander, MD\(^{6}\)

Author affiliations:  
1. Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, Oregon  
2. MD/PhD Program, School of Medicine, Oregon Health & Science University, Portland, Oregon  
3. School of Social Work, Portland State University, Portland, Oregon  
4. OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, Oregon  
5. Division of General Internal Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR  
6. Division of Hospital Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR

Running head: Classification of polysubstance use peri-hospitalization

Corresponding Author:  
Caroline King, MPH  
3181 Sam Jackson Park Road  
Portland, Oregon 97239  
e. kingca@ohsu.edu  
c. 724.991.6122

Article word count: 3626

Keywords: Inpatients, Opioid-Related Disorders, Amphetamine, Alcohol, Addictive Behavior, Hospitalization
Abstract

Background and Aims: Polysubstance use is common and contributes to morbidity and mortality of hospitalized patients, and yet little is known about patterns of substance use among hospitalized patients, or how an addiction consult service (ACS) might impact polysubstance use after discharge. The objective of this study was to identify patterns of substance use at admission and after discharge among hospitalized patients with substance use disorders seen by an ACS.

Design: Prospective cohort study. We used latent transition analysis of substance use scores at the time of hospital admission and 30 to 90 days post hospitalization.

Setting: Single, academic health center with an ACS in Portland, Oregon, from 2015-2018

Participants/Cases: Patients were eligible if they received a consult to the inpatient ACS.

Measurements: We used Addiction Severity Index -Lite scores to capture self-reported substance use at baseline and follow-up for heroin, other opioid, alcohol, amphetamine and cocaine use.

Findings: From 2015 to 2018, 486 individuals consented to participate. More than half of patients used more than one substance at baseline. We identified three patterns of substance use at baseline: 1) alcohol use dominant, 2) polysubstance use dominant, and 3) heroin and other opioid use dominant. Patients transitioned along five trajectories to three different follow-up profiles which showed lower endorsement of all substances used. 40.1% of patients newly endorsed abstinence of at least one substance at follow-up.

Conclusions: Polysubstance use is common in hospitalized patients with SUD and identifying patterns of polysubstance use can guide clinical management. Hospital providers should prepare to manage polysubstance use during hospitalization and hospitals should broaden care beyond interventions for opioid use disorder.
1. Introduction

Polysubstance use is increasingly common: over the last decade, opioid-related deaths have nearly tripled, but deaths among people using benzodiazepines, stimulants and synthetic opioids have matched or outpaced this trend (1). Polysubstance is the use of substances in different classes, but also within-class; for example, people who use both illicit methadone and heroin may have polysubstance use. In the past decade, on the west coast, in particular, there is increasing co-use of opioids and methamphetamine (2), although recent data suggests that methamphetamine use is emerging in the northeast (3). Hospitalizations from polysubstance use are also rising nationally, and polysubstance use is known to contribute to the morbidity and mortality of hospitalized patients (4).

Despite this, little is known about the care of people with polysubstance use during hospitalization, and most hospital-based interventions for substance use focus on a single substance (5). Hospitalization is an important care delivery environment warranting focused study as patients are at higher risk for overdose after hospital discharge (6); substance use influences other disease outcomes (e.g., effects of methamphetamine on cardiomyopathy, effects of alcohol on liver disease); hospitalization is a reachable moment to engage people in SUD treatment (7); and hospitals can be stigmatizing and traumatizing spaces for people with SUDs (8). It is unclear how hospitalization might affect polysubstance use, particularly in the context of an effective hospital-based intervention.

Addiction consult services (ACS) are emergent hospital-based organizational interventions (5) that reduce substance use severity (9) and increase patient engagement in treatment (7) during and post-hospitalization. While research has shown decreases in singular substance use by ACS (9) research to date has not explored if or how ACS influence patterns of polysubstance use.

Latent transition analysis (LTA) allows researchers to identify subgroups of people with similar patterns of variables within their study data (10, 11). LTA provides information about baseline behavior, follow-up behavior, and the probability of transitioning or changing over a period of time (11). LTA has been previously used to explore changes in singular substance use, particularly among patients with alcohol use disorder (12-21), and among adolescents and college students (12, 15, 22, 23), but has been used widely in other areas of change research as well (24-30). LTA is hypothesized to be of particular use in modeling changes in substance use (31). The objective of this study was to identify patterns of substance use at admission and after discharge among hospitalized patients with substance use disorders seen by an ACS.

2. Methods

2.1 Study setting and design

The Improving Addiction Care Team (IMPACT) is a hospital-based ACS at an academic health center in Portland, Oregon. IMPACT provides interprofessional addiction-related care from addiction providers (physicians, nurse practitioner, physician assistant), social workers, and recovery peers with lived experience (7). IMPACT patients are hospitalized for acute medical and surgical conditions (e.g. endocarditis, acute alcohol withdrawal, abscess), and generally are not seeking addiction treatment at time of hospitalization. Any hospital provider or social worker can refer a patient to IMPACT. Patients are eligible for referral if they have known or suspected SUD, other than exclusively tobacco use disorder. Interest in SUD treatment or reducing substance use is not required for IMPACT participation. IMPACT performs substance use assessments; initiates pharmacotherapy and behavioral SUD treatment when appropriate; provides rapid-access to post-hospital SUD care; and provides bridging peer support, in hospital and after discharge. Pharmacotherapy provided includes buprenorphine, methadone, and
extended-release naltrexone for opioid use disorder; acamprosate, naltrexone (extended-release and oral), and other medications for alcohol use disorder; bupropion and varenclene for tobacco use disorder; and occasionally bupropion or mirtazapine for people with alternate indications who also have a stimulant use disorder (32). Behavioral treatments include but are not limited to motivational interviewing, brief intervention, and contingency management. IMPACT offers harm reduction and embraces principles of trauma-informed care. Earlier studies describe IMPACT in detail (7, 33, 34). This project was approved by Oregon Health & Science University’s Institutional Review Board.

2.2 Participants
Between September 2015 and August 2018, IMPACT researchers consented and enrolled interested patients in an IMPACT evaluation study. All patients contacted by IMPACT were eligible to enroll. Patients readmitted at least six months after enrolling in this study were able to reenroll and repeat study surveys and interviews. This manuscript only includes data from participants’ first hospital admission in which they were enrolled in IMPACT research.

2.3 Data collection and measures
A research assistant who was not part of the clinical team administered the baseline survey to patients early in their hospitalization, and administered a follow-up survey 30 to 90 days after hospital discharge. If patients returned to the hospital within the 30 to 90 days after discharge, they were contacted during their hospital stay. This 20-minute survey asked questions related to demographics (e.g. income, partner status), substance use (e.g. days of use), and patient experience (e.g., care transition measure). Surveys included drug use items adapted from the Addiction Severity Index Lite (ASI Lite), a tool used to monitor substance use over time. ASI-lite items included measures of substance misuse of prescribed or illicit opioids including heroin, amphetamines, cocaine, methadone, cannabis, other opioids, and alcohol in the 30 days (35, 36). The other opioids category includes all non-prescribed opioids other than heroin and methadone, including fentanyl (35, 36). Versus other parts of the United States, overdose deaths attributable to fentanyl occur at lower rates in Oregon (37). All survey data was stored in REDCap (38).

2.4 Data analysis
2.4.1 Analyses
We used LTA to identify subgroups of patients by their ASI Lite substance use at baseline and follow-up, and estimated distributions of our population across these profiles. Latent transition analysis provides three key outputs: 1) estimated subgroup membership probabilities at baseline and follow-up, 2) transition probabilities across subgroups from baseline to follow-up, and 3) ASI-Lite response probabilities at each time for each subgroup (10, 11).

We first identified latent classes using participant ASI Lite responses for five variables: alcohol, heroin, other opioids (e.g. fentanyl), cocaine, and amphetamines (mostly methamphetamine). We excluded patients whose only substance use at baseline was methadone (n=9), cannabis (n=11), or both (n=6) because we were primarily interested in non-methadone opioids, alcohol and stimulants. We reclassified the ASI lite scores to reflect the number of times per week of use for each substance. We hypothesized that our data would have a zero-inflated Poisson distribution for each substance, and so included the following categorical classifications: 0 days of use per week (0 days of use reported), 1 day of use per week (1-4 days per month), 2 to 5 days of use per week (5-20 days per month), and more than 5 days of use per week (21 to 30 days per month).

Because we believed, a priori, our population to be heterogeneous based on clinical observations, we considered models that identified between two and six subgroups of patients. We used latent class
analysis to examine best fit models at baseline, and then tested if imposing measurement invariance over time (to allow subgroups to maintain the same meaning at baseline and follow-up) was appropriate using a likelihood-ratio test (nested G² test) (39).

2.4.2 Model selection
2.4.2.1 Latent Class Analysis
We calculated Log-likelihood, G-squared, Akaike information criterion (AIC), Bayesian information criterion (BIC), Bozdogan’s Criterion, adjusted Bayesian information criterion and entropy values from our models, as well as their degrees of freedom (Appendix 1). Following the work of Lanza & Bray, 2010 (28), we generated 1000 random sets of starting values for both our baseline and follow-up analyses in PROC LCA and also report the percentage of time the optimal solution was found among the seeds specified. Collins & Lanza, 2010 (11) suggest that higher solution stability can provide further reassurance that the maximum likelihood solution has been identified. Separately, Nyland et al, 2007 (40) found that the bootstrapped likelihood-ratio and, second to it, BIC value, were best in a simulation study at specifying the model, though BIC values tend to bias towards over-simplified models (41). While we initially planned to carry out the likelihood-ratio test to compare across models, we were only confident in our three-class models at baseline and follow-up because of the large drop off in solution stability of all other baseline models, and thus chose to proceed with three classes in our LTA. We provide our final code and model selection tables in Appendix 1.

2.4.2.2 Latent Transition Analysis
We calculated model fit statistics including log-likelihood, G-squared, AIC, and BIC for our latent transition model. We planned to consider invoking measurement invariance across time, which would have allowed our model’s subgroups to retain the same meanings over time. However, our likelihood ratio (nested G² test) was significant (p<0.001), and so we did not invoke measurement invariance (39).

2.4.2.3 Case examples
To illustrate patients’ transitions, we selected patients with high posterior probabilities (probability of belonging in each trajectory) of baseline and follow-up profile membership among each trajectory identified, and describe the patient’s presentation, interventions received during hospitalization from IMPACT, and qualitative excerpts, if the patient completed a follow-up interview.

2.4.2.4 Missing data
Before analyses, we dropped participants missing all baseline ASI Lite data. For participants who listed numbers of days of use of at least one drug (for example, heroin: 19 days), we replaced all other missing baseline values as 0 days (i.e. alcohol replaced as 0 days, cocaine replaced as 0 days, if missing at baseline), because we hypothesized that it was more likely that the person did not use the substance at baseline. We confirmed the rationale for this approach with the research assistant who collected the surveys. If the value was also missing at follow-up and the baseline value was imputed as zero, we imputed the follow-up value as zero.

LTA assumes that missing data is Missing at Random, and identifies the subgroup for a patient even if an outcome measure is missing. Thus, we included participants in our analysis who were missing follow-up data because we agreed that data could be Missing at Random (42).

We used Stata 15 to clean our data, and SAS PROC LCA & LTA (43) and SAS 9.4 to analyze data. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA.
3. Results
From 2015 to 2018, 486 individuals consented to participate. Nine participants had no baseline data, and the 51 participants who used methadone or cannabis exclusively and were dropped from the analysis (Figure 1). Among our final participant cohort, most were male (64.1%), white (77.5%), with health insurance (94.8%) and access to a usual source of primary care (65.3%). Over half (52.8%) of participants used at least two substances. Two-hundred and one (201) participants used only one substance at baseline. Of those, 50.7% used only alcohol, 21.9% used only other opioids, 16.9% used only amphetamines, and 10.4% used only heroin. Follow-up survey rates for people with any alcohol, heroin, other opioid, cocaine, or methamphetamine use at baseline ranged from 50.3% to 63.3% (59.1%, 50.3%, 58.8%, 63.3%, 52.8%, respectively). Most patients completed the follow-up survey while out of the hospital; fewer than 10% completed the follow-up survey during a readmission. The median length of hospital admission was 8 days (range=[1,118]). In Figure 2, we show baseline and follow-up ASI-Lite past 30-day drug use prevalence by individual substance, not accounting for polysubstance use.

3.1 Subgroup descriptions at baseline and follow-up
We identified three subgroups at baseline and three subgroups at follow-up (Figure 3). The three baseline subgroups were: 1) alcohol use dominant; 2) polysubstance use dominant; and 3) other opioids and heroin use dominant. In group 1, “alcohol use dominant”, 29.2% endorsed alcohol use 5 to 20 days per month, and 54.2% endorsed alcohol use more than 21 days per month. Additionally, nearly everyone abstained from using heroin in this group, and only 10.5% of participants used other opioids and amphetamines at least once a month. In group 2, “polysubstance use dominant”, 35.2% of participants used amphetamines 5 to 20 days per month, and 18.0% used amphetamines more than 21 days per month. Additionally, 19.6% used heroin 5 to 20 days per month and 47.5% used heroin more than 21 days per month. This population had varying levels of alcohol use (24.8% endorsed drinking at least one in the previous month) and other opioid use (38.9% endorsed other opioid use at least once in the previous month). Group 3, “other opioid and heroin use dominant”, had low probabilities of endorsing alcohol, amphetamines or cocaine use greater than 5 days in the previous month (all less than 5%). This group was more likely to endorse other opioid use over 21 days (44.8%) and heroin use over 21 days (6.1%), as well as other opioids and heroin at least 5 to 20 days (43.9% and 7.6%, respectively).

We estimated that at baseline, 31.1% of the population belonged to the alcohol use dominant group, 52.0% belonged to the polysubstance use dominant group, and 16.9% belonged to the heroin and other opioid use dominant group.

The three follow-up subgroups were: 1) lower alcohol use dominant; 2) lower polysubstance use dominant; 3) other opioid use/lower heroin use dominant. In the first follow-up subgroup, “lower alcohol use dominant”, participants had some other opioid use over 5 days per month (5.7%), with 16.6% endorsing alcohol use over 21 days per month. This group was unlikely to have reported amphetamine, cocaine, or heroin use over 5 days per month, and less than 2% were likely to have used amphetamine, heroin or cocaine at all during the month. 63.1% of this group had no alcohol use, and no one in this group was likely to have used heroin. The second group, “lower polysubstance use dominant”, had 16.7% of participants reporting at least 21 days of heroin use, with 23.9% likely to have endorsed using amphetamines between 5 and 30 days of the previous month. The final subgroup, “other opioid use/lower heroin use dominant” shows less than 2% of participants were likely to endorse 5 days or more of alcohol, amphetamine, cocaine or heroin use; however, 43.4% were likely to endorse using other opioids.
3.2 Transition probabilities
From baseline to follow-up, 100% of participants were likely to have transitioned from the alcohol use dominant to lower alcohol use dominant subgroup (Figure 3). 93.7% of participants transitioned from the polysubstance use dominant group to lower polysubstance use dominant group, and the remaining 6.3% transitioned to the other opioid use/lower heroin use dominant group. Among those in the other opioids and heroin use dominant group, 22.9% transitioned to the lower alcohol use dominant group, and 77.1% transitioned to the other opioid use/lower heroin use dominant group. In Table 3, we provide cases that illustrate the transition paths of patient subgroups using cases of patients probabilistically most likely to fall in each trajectory.

3.3 Participants abstaining at follow-up
In addition to our LTA, we report the number of participants who transitioned from any use to abstinence at follow-up. 203 (47.7%) of our 426 participants reported any alcohol use at baseline; 57 (28.1%) of those patients transitioned to 0 days of use at follow-up. 189 (44.4%) participants used heroin at least once at baseline, and 36 (19.0%) of those patients reported 0 days of use at follow-up. 170 (39.9%) reported other opioid use at baseline, and 36 (21.2%) of those participants reported no other opioid use at follow-up. 30 (7.0%) endorsed cocaine use at baseline, and 14 then reported no use at follow-up (46.7%). Finally, 195 (45.8%) participants used amphetamines at least once at baseline, and 55 (28.2%) of those participants reported no use at follow-up.

4. Discussion
Among patients seen by an ACS, we found three patterns of substance use at baseline and three distinct patterns at follow-up; patients moved through five trajectories among these patterns. Polysubstance use was common in patients seen by IMPACT. LTA classified 52.0% of patients in the polysubstance use dominant group, 16.9% in the other opioids and heroin use dominant group, and 31.1% in the alcohol use dominant profile at baseline. Follow-up profiles show lower levels of substance use than baseline profiles. While many participants continued to use some combination of substances, 40.1% patients reported abstinence of at least one substance they were using pre-hospitalization at follow-up.

Our results build on a growing body of literature related to polysubstance use. Earlier work found methamphetamine-related emergency department visits (44), hospitalizations (2), and health care costs (2) are rising, particularly in the western United States, and that rates of methamphetamine use among people who use heroin are also rising (45). Our study, which uses patient reported data as compared with administrative data, mirrors these findings. In our study at baseline, 45.8% of patients endorsed using amphetamines at least once in the previous 30 days, and more than half reported polysubstance use. Additionally, of the 269 patients who reported any opioid use at baseline, nearly three-quarters had polysubstance use, including use of alcohol (n=80, 29.7%), cocaine (n=25, 9.3%), or amphetamines (n=142, 52.8%) in the previous 30 days (n=187, 69.5%). The high prevalence of polysubstance use among hospitalized patients is important given earlier work that shows strong associations between polysubstance use and opioid-related overdose deaths, and recent work demonstrating the methamphetamine use is increasing among people who co-use opioids (46). One Massachusetts study found that 83% of people who died of opioid-related overdose deaths had other substances in their bloodstream, stimulants were the most common (4).

Other studies have identified patterns of polysubstance use at single timepoints. A study in Shanghai, China identified three patterns of polysubstance use (alcohol and heroin use, polysubstance use, and heroin and methamphetamine use) among treatment-seeking heroin-dependent adults and compared these patterns with treatment outcomes (47). Our groups are similar in identifying polysubstance use, but
Researchers in Australia examined patterns of polysubstance use among people who inject drugs, using a sample of national data and information about eighteen substances. They similarly identified patterns of polysubstance use (48). Our study is the first to explore transitions in polysubstance use after hospitalization and a hospital ACS intervention. Understanding polysubstance use patterns can guide clinical understanding of current presentations of SUD among hospitalized patients; further, these subgroups warrant further exploration for implications on engagement in care, treatment, and other outcomes among patients with SUD.

Our study had several important limitations. First, our study lacked a control group of patients who were not seen by an ACS. Thus, while it is likely that IMPACT services contributed to reduced substance use after discharge, our methods do not allow us to draw causal inference, and it is possible that other factors related to hospitalization contributed to changes in substance use. Second, our findings relied on patient self-reported substance use (35, 36), which may not always be accurate. Third, we had a limited sample size, preventing us from testing covariate associations with transition probabilities and potentially limiting our power to detect additional substance use patterns. Fourth, this is a single site study, and substance use patterns may represent regional trends not reflected in other settings. Fifth, we asked participants 30 to 90 days after hospital discharge to recall information about substance use in the 30 days after hospital discharge. It is possible participant responses are impacted by recall bias and may underestimate substance use after hospital discharge. Sixth, LTA assumes that data is Missing at Random. It is possible that some data is also Missing Completely at Random or Missing Not at Random. Finally, we adapted the ASI-Lite survey instrument as part of our baseline survey. To avoid respondent survey burden, we did not ask about some substance use, including inhalants, hallucinogens and benzodiazepines, which limited our understanding of how these substances are used in our study population.

Additionally, we are unsure why other opioid use remained high in our other opioid/lower heroin use group at follow-up. It is possible that patients included prescribed opioids in their survey response counts at follow-up, even though those opioids were not obtained illicitly or misused. Higher rates of other opioid use at follow-up may not reflect mis-use or illicit use, but instead reflect prescribed opioids related to care received during a medical or surgical hospitalization. Furthermore, the ASI-Lite may not fully capture the severity of substance use disorders. Other instruments may have provided a more comprehensive look at not only substance use, but also importantly its impact, on patient lives.

Our study has implications for clinical care, health systems, and future research. Because polysubstance use was common, hospital providers should be prepared to ask about, and care for, polysubstance use during hospitalization. Health systems should look to develop tools for patients, providers, hospitals, and communities at-large to help reduce potential harms from polysubstance use, regardless of patient plans to change use. Additionally, while first-line medications to treat OUD are an important, evidence-based pillar of care, addiction-related services in the inpatient setting should broaden beyond focused interventions for OUD. Future research should explore individual and population-level factors for emerging trends in polysubstance use, and identify additional ways to mitigate harm. Finally, recovery settings are predominately single substance focused. Future research should also explore how to best support patients who are in recovery in the setting of polysubstance use.

Our study found that following ACS consult, patterns of substance use decreased from baseline. These findings build on and support earlier work showing decreases in single substance use (9) in the setting of an ACS. The finding that subgroups of patients reduced substance use after care from an ACS is important, and adds to the growing literature (5, 7, 9) that supports the importance of hospital-based addiction care as an emerging standard of care (49). It is also important to highlight that even with
intensive hospital addiction consultation, many patients continue using substances. These findings underscore the need to integrate harm reduction into hospital care (50, 51), including supporting safer use practices, providing access to clean syringes, considering pre-exposure HIV prophylaxis, and providing naloxone and other strategies for overdose prevention.

Finally, the use of LTA to identify changes in substance use provide insights not achievable using traditional statistical methods. Wider use of subgroup analyses, including other machine learning techniques, may help guide the field towards a better understanding of heterogeneity among populations. Future work should explore differences in baseline patterns of substance use upon admission by region in the United States, as well as by hospital type and other patient and system level demographics. Hospital systems and communities should look to integrate and provide first-line, evidence-based, addiction care during hospitalization, regardless of the presence of an ACS, and shift towards a polysubstance use frame in caring for patients with SUD in the United States.

Ethical approval
This study was approved by Oregon Health & Science University’s Institutional Review Board (IRB #IRB00010846)

Funding
IMPACT is funded by Oregon Health & Science University and CareOregon.

CK, HE, and PTK were supported by grants from the National Institutes of Health, National Institute on Drug Abuse (UG1DA015815 / R01DA037441). KCP was supported by a grant from the National Institute on Drug Abuse (F30 DA044700UG).

This publication was also made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1TR002369 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research.

Role of funding source
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Contributors
CK and HE conceptualized the analysis idea. CK curated the data and designed and carried out the analysis. HE and PTK supervised the study. CK, HE, PTK and CN met to discuss analysis results and provide feedback and next steps monthly over the course of the study. HE, PTK and CN provided guidance for data visualization. CK wrote the original draft, and all authors reviewed, edited and approved the final manuscript.

Conflict of Interest
The authors have no competing interest to report. Dr. Korthuis serves as principal investigator on NIH-funded grants that receive donated study medication from Indivior (buprenorphine) and Alkermes (extended-release naltrexone).

Acknowledgements
We would like to thank the IMPACT patients for participating in this research.
References
1. CDC NCfHS. Multiple Cause of Death 1999–2017 on CDC Wide-ranging Online Data for Epidemiologic Research (CDC WONDER). 2018.
14. Cleveland MJ, Mallett KA, Turrisi R, Sell NM, Reavy R, Trager B. Using latent transition analysis to compare effects of residency status on alcohol-related consequences during the first two years of college. Addict Behav. 2018;87:276-82.
43. Lanza S DJ, Huang L, Wagner A, Collins LM. PROC LCA & PROC LTA Users' Guide Version 1.3.2. The Methodology Center, Penn State University. 2015.

**Tables**

1. **Baseline demographics of IMPACT participants, 2015-2018**

<table>
<thead>
<tr>
<th></th>
<th>Total (n=426)</th>
<th>Alcohol use dominant (n=135)*</th>
<th>Polysubstance use dominant (n=218)*</th>
<th>Other opioids and heroin use dominant (n=73)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, years (SD)</strong></td>
<td>43.9 (12.5)</td>
<td>47.5 (11.7)</td>
<td>40.9 (12.0)</td>
<td>46.3 (13.4)</td>
</tr>
<tr>
<td><strong>Gender</strong> Male</td>
<td>273 (64.1%)</td>
<td>90 (66.7%)</td>
<td>141 (64.7%)</td>
<td>42 (57.5%)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>Race Caucasian (n=422)</td>
<td>American Indian/Alaska Native</td>
<td>Asian</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>--------------</td>
<td>------------------------</td>
<td>-------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td>149 (35.0%)</td>
<td>330 (77.5%)</td>
<td>22 (5.2%)</td>
<td>2 (0.5%)</td>
</tr>
<tr>
<td></td>
<td>45 (33.3%)</td>
<td>104 (77.7%)</td>
<td>8 (5.9%)</td>
<td>1 (0.7%)</td>
</tr>
<tr>
<td></td>
<td>73 (33.5%)</td>
<td>166 (76.1%)</td>
<td>12 (5.5%)</td>
<td>1 (0.5%)</td>
</tr>
<tr>
<td></td>
<td>31 (42.5%)</td>
<td>60 (82.2%)</td>
<td>2 (2.7%)</td>
<td>0</td>
</tr>
</tbody>
</table>

*We used posterior probability values to assign patients to a subgroup for the purposes of displaying demographic information in Table 1.
Table 2. Latent transition patient examples

<table>
<thead>
<tr>
<th>Baseline Patient description</th>
<th>Follow-up Patient description</th>
<th>In-hospital interventions provided by IMPACT</th>
<th>Baseline ASI Lite Score</th>
<th>Follow-up ASI Lite Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol use dominant</td>
<td>Lower alcohol use dominant</td>
<td>• Diagnosed with severe AUD</td>
<td>Baseline: 0 0 0 0 0 4 2</td>
<td>Follow-up: 20 0 0 0 0 0 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Provided SUD education</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Administered extended release naltrexone</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Coordinated naltrexone transition to primary care</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Supported linkage to outpatient mental health care</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>27-year-old man with major depression and post-traumatic stress disorder admitted with suicidal ideation in the setting of acute alcohol intoxication</td>
<td></td>
<td>Baseline: 24 0 0 0 0 0 0</td>
<td>Follow-up: 20 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Polysubstance use dominant</td>
<td>Other opioid use/low lower heroin use dominant</td>
<td>• Diagnosed with severe OUD and benzodiazepine use disorder</td>
<td>Baseline: 0 30 4 2 2 0 3</td>
<td>Follow-up: 4 0 0 3 0 0 0</td>
</tr>
<tr>
<td></td>
<td>35-year-old man with a history of MRSA abscess admitted to MICU for acute renal failure (newly hemodialysis dependent), critical anemia, pericardial effusion, acute chest pain, and opioid/benzodiazapine. Reported starting using prescription opioids after a broken leg about 11 years ago, and moved to intravenous heroin for the last 10 years. Had</td>
<td>• Convened family meeting about treatment options post-discharge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Polysubstance use dominant | Less polysubstance use dominant | 31-year-old man with a history of OUD and MUD and homelessness admitted with cellulitis and bacteremia. Patient was largely unwilling to engage. Reported seven years of intravenous heroin use and occasional methamphetamine use. Initially ambivalent, but eventually interested in trying methadone. | • Started and up titrated methadone  
• Supported establishment with OTP  
• Helped obtain a photo ID and coordinated transportation (both barriers to engagement)  
• Connected patient with a shelter.  
• Provided naloxone  
• Provided peer support |
|---------------------------|---------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Other opioids and heroin use dominant | Other opioids use/low heroin use dominant | 51-year-old woman with hypertension, depression, endometriosis, and Hepatitis C admitted for spinal epidural abscess with adjacent soft tissue infection following decompression and | • Diagnosed with severe OUD and moderate MUD  
• Started methadone  
• Provided pain management with hydromorphone  
• Started SSRI for depression  
• Received social work SUD treatment |
drainage extending from cervical to lumbar vertebrae, MRSA bacteremia, stress cardiomyopathy and possible endocarditis. Five-year history of OUD; started with pills and transitioned to heroin. Last methamphetamine use two months prior to admission.

- Coordinated methadone at SNF
- Provided harm reduction education about safer use practices, naloxone, and family and housing interventions.
- Discharged to SNF to complete intravenous antibiotics with hydromorphone taper

| Other opioids and heroin use dominant | Lower alcohol use dominant | 62-year-old man with HIV/AIDS, COPD, Hepatitis C, opioid use disorder, chronic pain, and hypertension admitted for soft tissue abscesses and pain control. Last opioid use one month prior to admission though persistent occasional methamphetamine use until admission. | Started buprenorphine-naloxone
- Connected to primary care; HIV care and community resources
- Provided peer support | 1 | 12 | 0 | 7 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |

Alc=Alcohol use, Her= Heroin use, Amph= Amphetamine use, Oth Opi= Other Opioid use, Coc= Cocaine use, AUD= Alcohol use disorder, OUD=Opioid use disorder, MUD=methamphetamine use disorder, SNF= Skilled nursing facility, SUD= Substance use disorder; a period (.) indicates missing data
Figure 1. Participant flowchart

Patients referred to IMPACT at least once  
\( n=760 \)

\[\rightarrow\]

Approached for survey  
\( n=689 \)

\[\rightarrow\]

Consented for survey  
\( n=486 \)

\[\rightarrow\]

ASI not completed  
\( n=9 \)

\[\rightarrow\]

Excluded  
Only cannabis use reported (\( n=11 \))  
Only methadone use reported (\( n=8 \))  
Only cannabis & methadone use reported (\( n=6 \))  
No substance use reported in last 30 days (\( n=25 \))

\[\rightarrow\]

ASI Completed  
\( n=477 \)

\[\rightarrow\]

Not approached for survey  
\( n=71 \)

- Discharged/left before could be seen (46)
- Not available (23)
- In custody (1)
- Died before screened (1)

\[\rightarrow\]

Declined survey  
\( n=203 \)

\[\rightarrow\]

Final cohort  
\( n=426 \)
Figure 2. Sankey flowcharts of baseline and follow-up ASI Lite Scores, 2015-2018* (Print in Color)

*No use included 0 days of use per week (0 days of use reported); low use included 1 day of use per week (1-4 days per month); moderate use included 2 to 5 days of use per week (5-20 days per month); high use included >5 days of use per week (21-30 days per month).
Figure 3. Probabilities of item endorsement by subgroups at baseline and follow-up (Print in Color)
### Table 1. Model fit statistics for latent classes at baseline and follow-up with 1000 random starts

<table>
<thead>
<tr>
<th>Number of subgroups</th>
<th>Log-likelihood</th>
<th>G-squared</th>
<th>AIC</th>
<th>BIC</th>
<th>CAIC</th>
<th>ABIC</th>
<th>Entropy</th>
<th>Degrees of Freedom</th>
<th>Solution %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline models</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>-1965.43</td>
<td>483.41</td>
<td>545.41</td>
<td>671.09</td>
<td>702.09</td>
<td>572.72</td>
<td>0.87</td>
<td>992</td>
<td>8.0%</td>
</tr>
<tr>
<td>3</td>
<td>-1910.90</td>
<td>374.34</td>
<td>468.34</td>
<td>705.90</td>
<td>509.75</td>
<td>0.88</td>
<td>976</td>
<td>94.9%</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>-1889.47</td>
<td>331.49</td>
<td>457.49</td>
<td>712.92</td>
<td>775.92</td>
<td>513.00</td>
<td>0.94</td>
<td>960</td>
<td>5.0%</td>
</tr>
<tr>
<td>5</td>
<td>-1872.16</td>
<td>296.86</td>
<td>454.86</td>
<td>775.16</td>
<td>854.16</td>
<td>0.95</td>
<td>944</td>
<td>0.4%</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>-1855.19</td>
<td><strong>262.92</strong></td>
<td><strong>452.92</strong></td>
<td>838.09</td>
<td>933.09</td>
<td>536.62</td>
<td>0.90</td>
<td>928</td>
<td>2.2%</td>
</tr>
<tr>
<td><strong>Follow-up models</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>-819.59</td>
<td>120.66</td>
<td>182.66</td>
<td>308.28</td>
<td>339.28</td>
<td>209.91</td>
<td>0.69</td>
<td>992</td>
<td>92.4%</td>
</tr>
<tr>
<td>3</td>
<td>-807.18</td>
<td>95.83</td>
<td>189.83</td>
<td>380.28</td>
<td>427.28</td>
<td>231.13</td>
<td>0.83</td>
<td>976</td>
<td>22.0%</td>
</tr>
<tr>
<td>4</td>
<td>-798.23</td>
<td>77.94</td>
<td>203.94</td>
<td>459.23</td>
<td>522.23</td>
<td>259.30</td>
<td>0.55</td>
<td>960</td>
<td>23.5%</td>
</tr>
<tr>
<td>5</td>
<td>-791.86</td>
<td>65.21</td>
<td>223.21</td>
<td>543.32</td>
<td>622.32</td>
<td>292.63</td>
<td>0.83</td>
<td>944</td>
<td>0.7%</td>
</tr>
<tr>
<td>6</td>
<td>-785.86</td>
<td><strong>53.19</strong></td>
<td>243.19</td>
<td>628.14</td>
<td>723.14</td>
<td>326.67</td>
<td>0.68</td>
<td>928</td>
<td>0.2%</td>
</tr>
</tbody>
</table>

### Table 2. Model fit statistics for three group latent transition analysis, with and without measurement invariance

<table>
<thead>
<tr>
<th>Model type</th>
<th>Log-likelihood</th>
<th>G-squared</th>
<th>AIC</th>
<th>BIC</th>
<th>Degrees of Freedom</th>
</tr>
</thead>
<tbody>
<tr>
<td>With measurement invariance</td>
<td>-2757.11</td>
<td>1550.52</td>
<td>1656.52</td>
<td>1871.40</td>
<td>1048522</td>
</tr>
<tr>
<td>Without measurement invariance</td>
<td>-2650.89</td>
<td>1338.10</td>
<td>1534.10</td>
<td>1931.43</td>
<td>1048477</td>
</tr>
</tbody>
</table>

### Table 3. Subgroup item response probabilities and membership probabilities at baseline

<table>
<thead>
<tr>
<th></th>
<th>Alcohol use dominant</th>
<th>Polysubstance use dominant</th>
<th>Other opioids and heroin use dominant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Membership probability at baseline</td>
<td>0 days</td>
<td>1-4 days</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>31.1%</td>
<td>52.0%</td>
</tr>
<tr>
<td>Alcohol</td>
<td>0</td>
<td>75.2%</td>
<td>78.3%</td>
</tr>
<tr>
<td>Other opioids</td>
<td>89.5%</td>
<td>62.1%</td>
<td>0</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>89.5%</td>
<td>20.0%</td>
<td>94.7%</td>
</tr>
<tr>
<td>Cocaine</td>
<td>96.1%</td>
<td>90.1%</td>
<td>96.0%</td>
</tr>
<tr>
<td>Heroin</td>
<td>98.6%</td>
<td>24.2%</td>
<td>73.5%</td>
</tr>
<tr>
<td>Alcohol</td>
<td>16.7%</td>
<td>12.3%</td>
<td>19.0%</td>
</tr>
<tr>
<td>Other opioids</td>
<td>1.8%</td>
<td>19.2%</td>
<td>11.2%</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>8.2%</td>
<td>26.8%</td>
<td>5.3%</td>
</tr>
<tr>
<td>Cocaine</td>
<td>2.6%</td>
<td>7.5%</td>
<td>2.7%</td>
</tr>
<tr>
<td>Heroin</td>
<td>0.9%</td>
<td>8.9%</td>
<td>12.8%</td>
</tr>
<tr>
<td>Alcohol</td>
<td>29.2%</td>
<td>7.0%</td>
<td>2.7%</td>
</tr>
<tr>
<td>Other opioids</td>
<td>6.5%</td>
<td>17.0%</td>
<td>43.9%</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>0</td>
<td>35.2%</td>
<td>0</td>
</tr>
<tr>
<td>Cocaine</td>
<td>1.3%</td>
<td>1.5%</td>
<td>1.3%</td>
</tr>
<tr>
<td>Heroin</td>
<td>0.9%</td>
<td>19.6%</td>
<td>7.6%</td>
</tr>
<tr>
<td>Alcohol</td>
<td>54.2%</td>
<td>5.5%</td>
<td>0</td>
</tr>
<tr>
<td>Other opioids</td>
<td>2.3%</td>
<td>2.7%</td>
<td>44.8%</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>2.3%</td>
<td>18.0%</td>
<td>0</td>
</tr>
<tr>
<td>Cocaine</td>
<td>0</td>
<td>0.9%</td>
<td>0</td>
</tr>
<tr>
<td>Heroin</td>
<td>0.6%</td>
<td>47.3%</td>
<td>6.1%</td>
</tr>
</tbody>
</table>

Table 4. Subgroup item response probabilities and membership probabilities at follow-up
Table 5. Transition probabilities among subgroups from baseline to follow-up

<table>
<thead>
<tr>
<th>Membership probability at baseline</th>
<th>Follow-up</th>
<th>0 days</th>
<th>1-4 days</th>
<th>5-20 days</th>
<th>21-30 days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>35.0%</td>
<td>48.7%</td>
<td>16.3%</td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>63.1%</td>
<td>88.8%</td>
<td>89.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other opioids</td>
<td>92.0%</td>
<td>89.1%</td>
<td>28.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamines</td>
<td>98.6%</td>
<td>63.9%</td>
<td>98.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cocaine</td>
<td>98.3%</td>
<td>99.3%</td>
<td>98.6%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heroin</td>
<td>100%</td>
<td>63.3%</td>
<td>98.6%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

0 days: Membership probability at baseline 35.0%, 48.7%, 16.3%

1-4 days: Membership probability at baseline 15.0%, 7.4%, 9.3%

5-20 days: Membership probability at baseline 5.4%, 3.8%, 1.5%

21-30 days: Membership probability at baseline 16.6%, 0%, 0%

Table 5. Transition probabilities among subgroups from baseline to follow-up
### Baseline

<table>
<thead>
<tr>
<th></th>
<th>Alcohol use dominant</th>
<th>Polysubstance use dominant</th>
<th>Other opioids and heroin use dominant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100.0%</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>93.7%</td>
<td>6.3%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22.9%</td>
<td>77.1%</td>
</tr>
</tbody>
</table>

### SAS Code

Final 3 class model using Latent Transition Analysis

```
PROC LTA DATA = WORK.LTA_FIN OUTPOST=post_prob;
NSTATUS 3;
NTIMES 2;
ITEMS alc0 opi0 meth0 coc0 her0
   alc1 opi1 meth1 coc1 her1;
CATEGORIES 4 4 4 4;
SEED 975469647;
RUN;
```

Latent Class Analysis for baseline model

```
PROC LCA DATA = WORK.LTA_FIN;
NCLASS 3;
ITEMS alc0 opi0 meth0 coc0 her0;
CATEGORIES 4 4 4 4;
*MEASUREMENT time1 time2;
SEED 5489;
NSTARTS 1000;
RUN;
```

Latent Class Analysis for follow-up model

```
PROC LCA DATA = WORK.LTA_FIN;
NCLASS 3;
ITEMS alc1 opi1 meth1 coc1 her1;
CATEGORIES 4 4 4 4;
*MEASUREMENT time1 time2;
SEED 5489;
NSTARTS 1000;
RUN;
```